Baidyanath Pharma Private Limited - Due diligence report

A 360° intelligence report on Baidyanath Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth a…

1997-08-26 Kolkata, West Bengal Active Unlisted Active Compliant
Share
View plans
BP Baidyanath Pharma Private Limited

Baidyanath Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
94/100
Trust Score
Low Risk

Baidyanath Pharma Private Limited is assessed as Low Risk with a Trust Score of 94/100. Baidyanath Pharma Private Limited is an active private limited indian non-government company incorporated in 1997, operating in the Healthcare sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 13 Jun 2026 from the latest processed filings. Baidyanath Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
94/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
NEHA SHARMA 01234567 Director 01/04/2018 6 yrs Approved
AMEVE SHARMA 01234567 Director 01/04/2018 6 yrs Approved
RASHMI SHARMA 01234567 Director 01/04/2018 6 yrs Approved
RAM KRISHAN SHARMA 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 5 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 90
Growth signals & trust indicators
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 28+ years.
Active GST registration(s).
Distress signals & risk flags
No critical warning flags detected in the available data.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence95/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment92/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view85/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 14 events
30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
NEHA SHARMA
31 Mar 2025
Latest balance sheet
Filed with ROC
19 Nov 2024
Director appointed
NEHA SHARMA (Director)
31 Mar 2023
Share transfer (FY 2023)
666.00000000 shares to RASHMI SHARMA
Share transfer (FY 2023)
666.00000000 shares to RAM KRISHAN SHARMA
31 Mar 2020
Share transfer (FY 2020)
334.00000000 shares to RAM KRISHAN SHARMA
Share transfer (FY 2020)
334.00000000 shares to RASHMI SHARMA
Share transfer (FY 2020)
332.00000000 shares to AMEVE SHARMA
12 Mar 2012
Securities allotted
19000.00 Equity Shares - 19.00 Lakh raised
06 Jul 2011
Director appointed
AMEVE SHARMA (Director)
26 Aug 1997
Incorporated
Registered with Roc Kolkata
Director appointed
RASHMI SHARMA (Director)
Director appointed
RAM KRISHAN SHARMA (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Vandana Graphics Private Limited U74899DL1993PTC052942 Delhi, Delhi, India
Devam Multiservices Private Limited U72300UP2015PTC073466 Lucknow, Uttar Pradesh, India
Tip Top Fashions Private Limited U18101MH2003PTC140199 Mumbai, Maharashtra, India
Megha Compusoft Private Limited U72100MH1997PTC108160 Mumbai, Maharashtra, India
Kaprishi Pharma Private Limited U52602AS2018PTC018600 Guwahati, Assam, India
Satya Enterprises Private Limited U00330BR1995PTC006290 Patna-16, Bihar, India
Neuzen Technologies Private Limited U72200DL2021PTC376852 New Delhi, Delhi, India
Metropolis Metro Motors Private Limited U51200MH1970PTC014846 Mumbai, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Baidyanath Pharma Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Baidyanath Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Baidyanath Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 94/100, distress signals and MSME payment-delay disclosures - know whether Baidyanath Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Baidyanath Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Baidyanath Pharma Private Limited an active company?

Baidyanath Pharma Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Baidyanath Pharma Private Limited financially healthy?

Baidyanath Pharma Private Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.

Should I do business with Baidyanath Pharma Private Limited?

Its overall Trust Score is 94/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Baidyanath Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Baidyanath Pharma Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Baidyanath Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Baidyanath Pharma Private Limited?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.